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A commentary on
Successful therapies for Alzheimer’s dis-
ease: why so many in animal models and
none in humans?
by Franco R, Cedazo-Minguez A. Front
Pharmacol (2014) 5:146. doi:10.3389/ fphar.
2014.00146
The aim of this commentary is to com-
plement the review of Franco and Cedazo-
Minguez (1).
ALZHEIMER’S DISEASE AND AMYLOID
BETA
Defining characteristics of Alzheimer’s dis-
ease (AD) are memory defects, synaptic
alterations, presence of neuroinflamma-
tory mediators, and a progressive neurode-
generation. One of the histopathological
hallmarks of the disease is the presence
of amyloid beta (Aβ) plaques; however, it
seems that soluble oligomers, also called
Aβ-derive-diffusible-ligands (ADDLs), are
the really toxic species involved in the
pathogenesis of AD (2). ADDLs are a blend
of several sizes of oligomeric Aβ species (3).
This suggests that most of the effects on the
neurons cannot be attributed to interac-
tions with specific receptors, but rather to
interaction and alteration of the proteins
and lipids within the cell membranes (4).
ADDLs have been detected in AD patients
(5), increasing their content with severity
(6). Dimers isolated from AD brains impair
LTP, enhance LTD, reduce dendritic spines
density, and correlate with clinical state (7).
Also, they are able to induce hyperphos-
phorylation of Tau and neuritic dystrophy
(8). Soluble oligomers of Aβ are toxic for
the neurons (9). They also cause synaptic
dysfunction (10) through the activation of
caspase-3 (11). Moreover, the inflamma-
tory response characterized by the secre-
tion of various products is initiated by the
glial cells when these cells detect Aβ (12).
Thus, Aβ appears to be a decisive trigger for
the development of this neurodegenerative
disorder.
NEUROINFLAMMATION AND
NEURODEGENERATION, TWO OF THE
CHARACTERS IN THE PROGRESSION
OF THE DISEASE
The neuronal loss observed in the AD
brains, as occurs in other neurodegen-
erative diseases, is produced mainly by
apoptosis (13, 14). Sustained neuroinflam-
matory response contributes to the pro-
gression of the disease (15, 16), which
ultimately it strengthens the neuronal
death (17).
For their physiological importance,
both processes are highly regulated; conse-
quently, they can be harmful when deregu-
lated. Apoptosis can be initiated through
the mitochondria – intrinsic pathway –
or by the stimulation of death receptors
(DRs) – extrinsic pathway – [see Ref. (18)].
DRs are cell surface receptors that belong
to the TNF super-family. They are able to
trigger apoptosis upon ligand binding. DRs
and their ligands are expressed physiolog-
ically in the brain (19), with important
roles in brain development (20, 21) and
in cellular homeostasis in adulthood (22).
In neurons, in normal conditions, the acti-
vation of these receptors does not initiate
apoptosis (23, 24). Likewise, inflamma-
tion is generally a beneficial physiological
response. In fact, it has been described that
the initial glial inflammatory response in
AD is protective (25, 26).
TNFα IN THE CROSS-ROAD BETWEEN
INFLAMMATION AND APOPTOSIS
In brain, TNFα plays a central role in neu-
roinflammation, apoptosis, and also in the
control of the synaptic strength (27, 28).
The TNFα gene maps within the class III
region of human leukocyte antigen (HLA).
Several polymorphisms were detected asso-
ciated to AD in this region, and systematic
meta-analyses concluded that TNFα is a
susceptibility gene in the disease (29). High
levels of TNFα have been detected in AD
patients (30, 31). TNF system has been pro-
posed as a neurotherapeutic target (32),
and its role in animal models of AD has
been reported (33–35). However, its func-
tion in the disease is not clear. It has been
described that TNFα is a contributor of the
disease (36, 37), although also that it can
protect from the Aβ toxicity (38, 39).
TNFα can stimulate two signaling path-
ways, survival or death (40). The induc-
tion of survival pathways depend on NFκB
(40) and/or FLIP-L-dependent activation
of ERK (41). In normal conditions, TNFα
is not toxic for the neurons, indicating
that several regulatory proteins prevent the
induction of apoptosis at various stages of
TNF signaling (42). Expressed exclusively
in neurons, the long form of Fas apop-
totic inhibitory molecule (FAIM) protein
(FAIM-L) is able to regulate the signaling
of TNFα. The down-regulation of FAIM-L
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sensitizes neurons to death induced by
TNFα and also by FAS (43). In Parkinson’s
disease, it has been proposed that FAIM-L
expression could be reduced in dopaminer-
gic neurons,being then this type of neurons
more vulnerable to FAS-induced death
(44). We have evidences that ADDLs reduce
the expression of FAIM-L. The reduction of
FAIM-L changes the response mediated by
TNFα against the Aβ toxicity, from protec-
tion to a contributor in the neuronal death,
thus, accelerating the neurodegenerative
process (paper under review).
NEW PERSPECTIVES IN FINDING
POTENTIAL TARGETS
FAIM-L, modulating the function of the
TNFα in neurons, would be an example
of target molecule able to ameliorate both
neurodegeneration and deleterious neu-
roinflammation. Although speculative, it
is possible to hypothesize that the reduc-
tion in the neuronal loss would result in
an improvement also in the cognition. Aβ
is able to cause all the features observed
in the disease, thus, targets able to act in
more than one of the aspects of the dis-
ease would be more useful. However, this
type of strategy only would be effective
in the prevention of disease progression
rather than in the prevention of the disease.
Moreover, whereas we do not have good
biomarkers for early detection, it seems dif-
ficult that potential AD patients (99% of
the cases correspond to the non-familiar or
sporadic) without any symptom or diagno-
sis would take drugs to prevent AD in the
future, unless these were supplements or
healthy habits. Thus, therapies able to pre-
vent the progression of the disease acquire
greater relevance.
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